Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRISPR Therapeutics AGCRSP · Entity 3852 | Chief Scientific Officer | October 24, 2016 | February 10, 2017 |
| Q32 Bio Inc.QTTB · Entity 5594 | Director | June 12, 2026 | July 22, 2026 |
| Vor Biopharma Inc.VOR · Entity 4763 | Director | May 22, 2025 | May 23, 2025 |
| Yarrow Bioscience, Inc.YARW · Entity 6871 | Director | July 27, 2026 | July 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRISPR Therapeutics AG
Report date October 24, 2016 · Filed February 10, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 505,217 |
Reported balance
After 2016-10-24 transaction · row 1
1 source rowRow 1 · 2016-10-24 · Conversion · Acquired 55,217 · Balance 505,217 F1: These securities were convertible at any time on a one-for-one basis into shares of the Issuer's Common Stock at the holder's election and automatically upon the closing of the Issuer's initial public offering. These securities do not have an expiration date. |
| Common SharesSEC Table I · non-derivative | IndirectBy wife | 505,617 |
Reported balance
After 2016-10-24 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2016-10-24 · Purchase · Acquired 400 · Balance 505,617 |
| Series B Preferred SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2016-10-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-10-24 · Conversion · Disposed 55,217 · Balance 0 F1: These securities were convertible at any time on a one-for-one basis into shares of the Issuer's Common Stock at the holder's election and automatically upon the closing of the Issuer's initial public offering. These securities do not have an expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities were convertible at any time on a one-for-one basis into shares of the Issuer's Common Stock at the holder's election and automatically upon the closing of the Issuer's initial public offering. These securities do not have an expiration date.
Q32 Bio Inc.
Report date June 12, 2026 · Filed July 22, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.64 · Expires 2036-06-11 | Direct | 10,826 |
Reported balance
After 2026-06-12 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 10,826 · Balance 10,826 F1: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F2: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.
F2: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
Vor Biopharma Inc.
Report date May 22, 2025 · Filed May 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.19 · Expires 2035-05-21 | Direct | 30,000 |
Reported balance
After 2025-05-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-22 · Grant · Acquired 30,000 · Balance 30,000 F1: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) May 22, 2026 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) May 22, 2026 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.
Yarrow Bioscience, Inc.
Report date July 27, 2026 · Filed July 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.19 · Expires 2036-04-17 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-07-27 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Effective as of July 27, 2026 (the "Effective Time"), a wholly owned subsidiary of VYNE Therapeutics Inc. ("VYNE") merged with and into Yarrow Bioscience, Inc. ("Yarrow") with Yarrow continuing as a wholly owned subsidiary of VYNE and the surviving corporation of the merger (the "Merger") under the name "Yarrow Bioscience Operating Company Corp." In connection with the completion of the Merger, VYNE changed its name to "Yarrow Bioscience, Inc." (hereinafter, the "Issuer"). F2: Represents options to purchase shares of common stock, par value $0.0001, of the Issuer ("Issuer Common Stock") received by the Reporting Person in the Merger in exchange for options to purchase shares of common stock of Yarrow held by the Reporting Person prior to the Merger. At the Effective Time, the Issuer assumed each such Yarrow option, whether vested or unvested, and converted it into an option to purchase shares of Issuer Common Stock on the same terms and conditions as were in effect immediately prior to the Effective Time. F3: This option represents a right to purchase 175,639 shares of Issuer Common Stock, one quarter of which will vest on April 17, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective as of July 27, 2026 (the "Effective Time"), a wholly owned subsidiary of VYNE Therapeutics Inc. ("VYNE") merged with and into Yarrow Bioscience, Inc. ("Yarrow") with Yarrow continuing as a wholly owned subsidiary of VYNE and the surviving corporation of the merger (the "Merger") under the name "Yarrow Bioscience Operating Company Corp." In connection with the completion of the Merger, VYNE changed its name to "Yarrow Bioscience, Inc." (hereinafter, the "Issuer").
F2: Represents options to purchase shares of common stock, par value $0.0001, of the Issuer ("Issuer Common Stock") received by the Reporting Person in the Merger in exchange for options to purchase shares of common stock of Yarrow held by the Reporting Person prior to the Merger. At the Effective Time, the Issuer assumed each such Yarrow option, whether vested or unvested, and converted it into an option to purchase shares of Issuer Common Stock on the same terms and conditions as were in effect immediately prior to the Effective Time.
F3: This option represents a right to purchase 175,639 shares of Issuer Common Stock, one quarter of which will vest on April 17, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Merus N.V.
Report date December 12, 2025 · Filed December 12, 2025
Section 16 reporting ended · disclosed 2025-12-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | IndirectAnte S Lundberg Qualified Annuity Interest Trust XI | 0 |
Reported balance
After 2025-12-12 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-12-12 · Other · Disposed 30,297 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including the Shares tendered by the reporting person, in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries. |
| Common SharesSEC Table I · non-derivative | IndirectAnte S Lundberg Qualified Annuity Int Trust X | 0 |
Reported balance
After 2025-12-12 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-12-12 · Other · Disposed 16,372 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including the Shares tendered by the reporting person, in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries. |
| Common SharesSEC Table I · non-derivative | IndirectKatrina Lundberg 2018 Irrevocable Trust | 0 |
Reported balance
After 2025-12-12 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2025-12-12 · Other · Disposed 9,191 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including the Shares tendered by the reporting person, in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries. |
| Common SharesSEC Table I · non-derivative | IndirectMadeleine Lundberg 2018 Irrevocable Trust | 0 |
Reported balance
After 2025-12-12 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2025-12-12 · Other · Disposed 9,191 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including the Shares tendered by the reporting person, in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries. |
| Common SharesSEC Table I · non-derivative | IndirectKristian Ante Lundberg 2018 Irrevocable Trust | 0 |
Reported balance
After 2025-12-12 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2025-12-12 · Other · Disposed 9,192 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including the Shares tendered by the reporting person, in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries. |
| Common SharesSEC Table I · non-derivative | IndirectEmily Lundberg 2018 Irrevocable Trust | 0 |
Reported balance
After 2025-12-12 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2025-12-12 · Other · Disposed 9,192 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including the Shares tendered by the reporting person, in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.52 · Expires 2030-01-03 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-12-12 · Disposition to issuer · Disposed 312,620 · Balance 0 F3: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.43 · Expires 2031-02-16 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-12-12 · Disposition to issuer · Disposed 351,628 · Balance 0 F3: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.65 · Expires 2035-01-29 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-12-12 · Disposition to issuer · Disposed 300,000 · Balance 0 F3: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.09 · Expires 2034-01-31 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-12-12 · Disposition to issuer · Disposed 360,000 · Balance 0 F3: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.07 · Expires 2033-02-02 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2025-12-12 · Disposition to issuer · Disposed 380,000 · Balance 0 F3: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.61 · Expires 2032-01-31 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2025-12-12 · Disposition to issuer · Disposed 295,000 · Balance 0 F3: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including the Shares tendered by the reporting person, in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time.
F2: The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries.
F3: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 23, 2024 Filed May 28, 2024 20:10 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001415889-24-014649 · form4-05282024_040517.xml · derivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-05-22 F1 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) May 23, 2025 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| May 07, 2024 Filed May 9, 2024 16:30 UTC | Merus N.V. MRUS · Entity 70740 | GrantShare Option (right to buy) · Derivative | 360,000 | $0.00 Strike: $36.09 | $0.00 |
DisclosureSEC source: 0000950170-24-057086 · ownership.xml · derivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 360,000 Underlying: Common Shares · 360,000 shares Expires 2034-01-31 F1 · date: On February 1, 2024, the Board of Directors approved the grant of options to purchase the common shares, at an exercise price of $36.09 per share, subject to the Company's general meeting resolving upon, and the Board having implemented through an amendment to the Company's articles of association, an increase in the authorized share capital sufficient to satisfy the award set forth (the "Shareholder Approval Condition"). On May 7, 2024, the shareholders approved the amendment to the Company's articles of association, including the increase in the authorized share capital satisfying the Shareholder Approval Condition. F2 · derivative.exercise_date: Options vest over a four-year period from January 1, 2024. 25% vest on January 1, 2025 and in 36 equal monthly installments thereafter. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 21:25 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 12,767 | $0.00 Strike: $16.82 | $0.00 |
DisclosureSEC source: 0000950170-24-037368 · ownership.xml · derivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,767 Underlying: Common Stock · 12,767 shares Expires 2034-03-24 F1 · derivative.exercise_date: One-third of the shares underlying this option shall vest and become exercisable on March 25, 2025, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| May 26, 2023 Filed Jun 2, 2023 20:34 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $4.79 | $0.00 |
DisclosureSEC source: 0001209191-23-033803 · doc4.xml · derivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-05-25 F1 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) May 26, 2024 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 16:23 UTC | Merus N.V. MRUS · Entity 70740 | GrantShare Option (right to buy) · Derivative | 380,000 | $0.00 Strike: $16.07 | $0.00 |
DisclosureSEC source: 0001209191-23-006850 · doc4.xml · derivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,000 Underlying: Common Shares · 380,000 shares Expires 2033-02-02 F1 · derivative.exercise_date: Options vest over a four-year period from January 1, 2023. 25% vest on January 1, 2024 and in 36 equal monthly installments thereafter. Read SEC document |
| November 03, 2022 Filed Nov 3, 2022 14:07 UTC | Merus N.V. MRUS · Entity 70740 | PurchaseCommon Shares | 14,706 | $14.38 | $211,431.10 |
DisclosureSEC source: 0001209191-22-055466 · doc4.xml · nonDerivative · entry 3 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,576 F1 · shares: Purchased pursuant to 10B5-1 plan dated 6/10/2022 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.36 to $16.00, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| August 22, 2022 Filed Aug 23, 2022 16:09 UTC | Merus N.V. MRUS · Entity 70740 | PurchaseCommon Stock | 5,826 | $22.92 | $133,558.14 |
DisclosureSEC source: 0001209191-22-047168 · doc4.xml · nonDerivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,870 F1 · shares: Purchased in pursuant to 10B5-1 plan dated 6/10/2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.73 to $23.00, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| August 19, 2022 Filed Aug 22, 2022 15:02 UTC | Merus N.V. MRUS · Entity 70740 | PurchaseCommon Stock | 704 | $22.99 | $16,186.93 |
DisclosureSEC source: 0001209191-22-046994 · doc4.xml · nonDerivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,044 F1 · shares: Purchased in pursuant to 10B5-1 plan dated 6/10/2022 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.99 to $23.00, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above Read SEC document |
| July 12, 2022 Filed Jul 13, 2022 10:13 UTC | Merus N.V. MRUS · Entity 70740 | PurchaseCommon Shares | 4,340 | $22.97 | $99,684.59 |
DisclosureSEC source: 0001209191-22-042002 · doc4.xml · nonDerivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,340 F1 · shares: Sold in pursuant to 10B5-1 plan dated 6/10/22 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.75 to $23.00, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 21:07 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantStock Option (right to buy) · Derivative | 16,911 | $0.00 Strike: $4.26 | $0.00 |
DisclosureSEC source: 0001209191-22-037512 · doc4.xml · derivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,911 Underlying: Common Stock · 16,911 shares Expires 2032-06-13 F1 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 14:02 UTC | Merus N.V. MRUS · Entity 70740 | GrantShare Option (right to buy) · Derivative | 295,000 | $0.00 Strike: $24.61 | $0.00 |
DisclosureSEC source: 0001209191-22-006290 · doc4.xml · derivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,000 Underlying: Common Shares · 295,000 shares Expires 2032-01-31 F1 · derivative.exercise_date: Options vest over a four-year period from January 1, 2022. 25% vest on January 1, 2023 and in 36 equal monthly installments thereafter. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 15:56 UTC | Merus N.V. MRUS · Entity 70740 | Exercise / conversionShare Option (right to buy) · Derivative | 12,627 | $13.52 Strike: $13.52 | $170,717.04 |
DisclosureSEC source: 0001209191-21-049593 · doc4.xml · derivative · entry 4 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,120 Underlying: Common Shares · 12,627 shares Expires 2030-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options vest over a four-year period from January 1, 2020. 25% vest on January 1, 2021 and in 36 equal monthly installments thereafter. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 15:56 UTC | Merus N.V. MRUS · Entity 70740 | Exercise / conversionShare Option (right to buy) · Derivative | 2,373 | $12.54 Strike: $12.54 | $29,757.42 |
DisclosureSEC source: 0001209191-21-049593 · doc4.xml · derivative · entry 3 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,797 Underlying: Common Shares · 2,373 shares Expires 2029-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options vest over a three-year period commencing March 19, 2019. One-third vest after one year and in 24 equal monthly installments thereafter. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 15:56 UTC | Merus N.V. MRUS · Entity 70740 | Exercise / conversionCommon Shares | 2,373 | $12.54 | $29,757.42 |
DisclosureSEC source: 0001209191-21-049593 · doc4.xml · nonDerivative · entry 2 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 15:56 UTC | Merus N.V. MRUS · Entity 70740 | Exercise / conversionCommon Shares | 12,627 | $13.52 | $170,717.04 |
DisclosureSEC source: 0001209191-21-049593 · doc4.xml · nonDerivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 19:18 UTC | Merus N.V. MRUS · Entity 70740 | GiftCommon Shares | 74,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-023481 · doc4.xml · nonDerivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On March 25, 2021, the reporting person transferred 74,000 shares of Issuer common shares to a family trust of which the reporting person is trustee. The reporting person and members of his immediate family are the sole beneficiaries of the trust. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 16:00 UTC | Merus N.V. MRUS · Entity 70740 | Exercise / conversionShare Option (right to buy) · Derivative | 63,170 | $0.00 Strike: $13.52 | $0.00 |
DisclosureSEC source: 0001209191-21-016770 · doc4.xml · derivative · entry 4 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,747 Underlying: Common Shares · 63,170 shares Expires 2030-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options vest over a four-year period from January 1, 2020. 25% vest on January 1, 2021 and in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 16:00 UTC | Merus N.V. MRUS · Entity 70740 | Exercise / conversionShare Option (right to buy) · Derivative | 10,830 | $0.00 Strike: $12.54 | $0.00 |
DisclosureSEC source: 0001209191-21-016770 · doc4.xml · derivative · entry 3 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,170 Underlying: Common Shares · 10,830 shares Expires 2029-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options vest over a three-year period commencing March 19, 2019. One-third vest after one year and in 24 equal monthly installments thereafter. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 16:00 UTC | Merus N.V. MRUS · Entity 70740 | Exercise / conversionCommon Shares | 63,170 | $13.52 | $854,058.40 |
DisclosureSEC source: 0001209191-21-016770 · doc4.xml · nonDerivative · entry 2 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 16:00 UTC | Merus N.V. MRUS · Entity 70740 | Exercise / conversionCommon Shares | 10,830 | $12.54 | $135,808.20 |
DisclosureSEC source: 0001209191-21-016770 · doc4.xml · nonDerivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 16:00 UTC | Merus N.V. MRUS · Entity 70740 | GrantShare Option (right to buy) · Derivative | 368,000 | $0.00 Strike: $24.43 | $0.00 |
DisclosureSEC source: 0001209191-21-011775 · doc4.xml · derivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,000 Underlying: Common Shares · 368,000 shares Expires 2031-02-16 F1 · derivative.exercise_date: Options vest over a four-year period from January 1, 2021. 25% vest on January 1, 2022 and in 36 equal monthly installments thereafter. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 22:14 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantStock Option (right to buy) · Derivative | 16,900 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008886 · doc4.xml · derivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,900 Underlying: Common Stock · 16,900 shares Expires 2031-02-04 F1 · derivative.exercise_date: 1/36th of the shares underlying the option vest in equal monthly installments commencing on March 5, 2021, provided that the Reporting Person remains continuously engaged by the Issuer on each such vesting date. Read SEC document |
| January 03, 2020 Filed Jan 6, 2020 17:00 UTC | Merus N.V. MRUS · Entity 70740 | GrantShare Option (right to buy) · Derivative | 414,917 | $0.00 Strike: $13.52 | $0.00 |
DisclosureSEC source: 0001209191-20-001952 · doc4.xml · derivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Director · President, CEO & PFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 414,917 Underlying: Common Shares · 414,917 shares Expires 2030-01-03 F1 · derivative.exercise_date: Options vest over a four-year period from January 1, 2020. 25% vest on January 1, 2021 and in 36 equal monthly installments thereafter. Read SEC document |
| October 24, 2016 Filed Feb 10, 2017 19:16 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionSeries B Preferred Shares · Derivative | 55,217 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-003419 · doc4.xml · derivative · entry 3 Lundberg Sven Ante · CIK 0001682126 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 55,217 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These securities were convertible at any time on a one-for-one basis into shares of the Issuer's Common Stock at the holder's election and automatically upon the closing of the Issuer's initial public offering. These securities do not have an expiration date. F1 · price: These securities were convertible at any time on a one-for-one basis into shares of the Issuer's Common Stock at the holder's election and automatically upon the closing of the Issuer's initial public offering. These securities do not have an expiration date. F1 · derivative.exercise_date: These securities were convertible at any time on a one-for-one basis into shares of the Issuer's Common Stock at the holder's election and automatically upon the closing of the Issuer's initial public offering. These securities do not have an expiration date. F1 · derivative.expiration_date: These securities were convertible at any time on a one-for-one basis into shares of the Issuer's Common Stock at the holder's election and automatically upon the closing of the Issuer's initial public offering. These securities do not have an expiration date. Read SEC document |
| October 24, 2016 Filed Feb 10, 2017 19:16 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | PurchaseCommon Shares | 400 | $14.00 | $5,600.00 |
DisclosureSEC source: 0000899243-17-003419 · doc4.xml · nonDerivative · entry 2 Lundberg Sven Ante · CIK 0001682126 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 505,617 Read SEC document |
| October 24, 2016 Filed Feb 10, 2017 19:16 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | ConversionCommon Shares | 55,217 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-003419 · doc4.xml · nonDerivative · entry 1 Lundberg Sven Ante · CIK 0001682126 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 505,217 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These securities were convertible at any time on a one-for-one basis into shares of the Issuer's Common Stock at the holder's election and automatically upon the closing of the Issuer's initial public offering. These securities do not have an expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.